Chemoinformaics analysis of (-)-(7R,9R,11R-7-N-METHYL-11(PROP-2-ENYL)CYTISINE
Molecular Weight | 190.246 | nRot | 0 |
Heavy Atom Molecular Weight | 176.134 | nRig | 16 |
Exact Molecular Weight | 190.111 | nRing | 3 |
Solubility: LogS | 0.63 | nHRing | 3 |
Solubility: LogP | 0.508 | No. of Aliphatic Rings | 2 |
Acid Count | 0 | No. of Aromatic Rings | 1 |
Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 28 | No. of Aliphatic Hetero Cycles | 2 |
No. of Heavy Atom | 14 | No. of Aromatic Carbocycles | 0 |
nHetero | 3 | No. of Aromatic Hetero Cycles | 1 |
nBridge Head | 2 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 1 |
No. of Carbon atom | 11 | No. of Saturated Rings | 1 |
No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
No. of Oxygen atom | 1 | No. of Arom Bond | 6 |
nHA | 3 | APOL | 30.7071 |
nHD | 1 | BPOL | 17.1929 |
QED | 0.648 |
Synth | 4.046 |
Natural Product Likeliness | -0.211 |
NR-PPAR-gamma | 0.007 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Rejected |
Pgp-inh | 0.001 |
Pgp-sub | 0.002 |
HIA | 0.01 |
CACO-2 | -4.815 |
MDCK | 0.00000382 |
BBB | 0.96 |
PPB | 0.170383 |
VDSS | 1.98 |
FU | 0.796488 |
CYP1A2-inh | 0.063 |
CYP1A2-sub | 0.266 |
CYP2c19-inh | 0.04 |
CYP2c19-sub | 0.743 |
CYP2c9-inh | 0.006 |
CYP2c9-sub | 0.098 |
CYP2d6-inh | 0.677 |
CYP2d6-sub | 0.716 |
CYP3a4-inh | 0.06 |
CYP3a4-sub | 0.331 |
CL | 7.092 |
T12 | 0.319 |
hERG | 0.137 |
Ames | 0.752 |
ROA | 0.825 |
SkinSen | 0.223 |
Carcinogencity | 0.595 |
EI | 0.04 |
Respiratory | 0.81 |
NR-Aromatase | 0.002 |
Antiviral | No |
Prediction | 0.715532 |